This portfolio has invested ___ in equity and debt securities of ___ firms, which during brought ___ new medicines to the home market of the portfolio's beneficiaries: .
These medicines are expected to add ___ years of healthy life to patients in the home market, thus alleviating ___% of the total disease burden in the home market.
Based on the portfolio's ownership share in the producing firms, which averages at ___%, attributed impact of the portfolio is ___ days of healthy life (___% of the total disease burden in the home market).
This portfolio has invested ___ in equity and debt of ___ public and ___ private firms, which rely on capital markets to fund new R&D, which would not otherwise be funded.
During the portfolio made ___ of additional such investments.
During these capital-markets-funded firms brought ___ new medicines to the home market of the portfolio's beneficiaries: . These medicines are expected to add ___ years of healthy life to patients, thus alleviating ___% of the total disease burden in the home market.
Based on the portfolio's ownership share in the capital-markets-funded producing firms, which averages at ___%, attributed impact of the portfolio is ___ days of healthy life (___% of the total disease burden in the home market).